Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms

Oncogene

Volumn 32, Issue 10, 2013, Pages 1316-1329

  Law, M E ^a,b   Corsino, P E ^a,b   Jahn, S C ^a,b   Davis, B J ^a,b   Chen, S ^a   Patel, B ^a,b   Pham, K ^a,b   Lu, J ^a,b   Sheppard, B ^a   Norgaard P ^c   Hong, J ^d   Higgins, P ^e   Kim, J S ^a,b,f   Luesch, H ^a,b   Law, B K ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d DUKE UNIVERSITY   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

breast cancer; E cadherin; glucocorticoid; HDAC inhibitor; invasion; PAI 1

Indexed keywords

CELL PROTEIN; CUB DOMAIN CONTAINING PROTEIN 1; DEXAMETHASONE; GLUTATHIONE TRANSFERASE; GREEN FLUORESCENT PROTEIN; HISTONE DEACETYLASE INHIBITOR; LARGAZOLE; PLAKOGLOBIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRICHOSTATIN A; UNCLASSIFIED DRUG; UVOMORULIN; VORINOSTAT;

ANIMAL TISSUE; ARTICLE; BASAL LIKE BREAST CANCER; CANCER CELL; CANCER INVASION; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM VESICLE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; WILD TYPE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874763834     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.138     Document Type: Article

References (64)

1. Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA et al. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 2011; 18: 2851-2857.
2. Pazaiti A, Fentiman IS. Basal phenotype breast cancer: implications for treatment and prognosis. Womens Health 2011; 7: 181-202.
3. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005; 17: 499-508.
4. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008; 27: 6920-6929.
5. Papageorgis P, Lambert AW, Ozturk S, Gao F, Pan H, Manne U et al. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res 2010; 70: 968-978.
6. Ou JN, Torrisani J, Unterberger A, Provencal N, Shikimi K, Karimi M et al. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 2007; 73: 1297-1307.
7. Corsino PE, Davis BJ, Norgaard PH, Parker NN, Law M, Dunn W et al. Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component. Neoplasia 2008; 10: 1240-1252.
8. Facina G, Lopes-Costa PV, Dos Santos AR, De Vasconcelos-Valenca RJ, Pinho- Sobral AL, Ferreira-Filho CP et al. Immunohistochemical expression of E-cadherin in sclerosing adenosis, ductal carcinoma in situ and invasive ductal carcinoma of the breast. Diagn Cytopathol 2010; 38: 235-238.
9. Baum B, Georgiou M. Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling. J Cell Biol 2011; 192: 907-917.
10. Heuberger J, Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb Perspect Biol 2010; 2: a002915.
11. Daniel JM. Dancing in and out of the nucleus: p120(ctn) and the transcription factor Kaiso. Biochim Biophys Acta 2007; 1773: 59-68.
12. Taori K, Paul VJ, Luesch H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc 2008; 130: 1806-1807.
13. Ying Y, Taori K, Kim H, Hong J, Luesch H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc 2008; 130: 8455-8459.
14. Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA, Byers SW. Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res 1999; 59: 947-952.
15. Feltes CM, Kudo A, Blaschuk O, Byers SW. An alternatively spliced cadherin-11 enhances human breast cancer cell invasion. Cancer Res 2002; 62: 6688-6697.
16. Lombaerts M, van Wezel T, Philippo K, Dierssen JW, Zimmerman RM, Oosting J et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-To-mesenchymal transition in breast cancer cell lines. Br J Cancer 2006; 94: 661-671.
17. Matsuyoshi N, Hamaguchi M, Taniguchi S, Nagafuchi A, Tsukita S, Takeichi M. Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts. J Cell Biol 1992; 118: 703-714.
18. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM et al. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993; 120: 757-766.
19. Hiscox S, Jiang WG. Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun 1999; 261: 406-411.
20. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 2005; 24 5333-5343.
21. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B et al. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res 2009; 15: 2311-2322.
22. Uekita T, Tanaka M, Takigahira M, Miyazawa Y, Nakanishi Y, Kanai Y et al. CUBdomain- containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol 2008; 172: 1729-1739.
23. Liu H, Ong SE, Badu-Nkansah K, Schindler J, White FM, Hynes RO. CUB-domaincontaining protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci USA 2011; 108: 1379-1384.
24. He Y, Wortmann A, Burke LJ, Reid JC, Adams MN, Abdul-Jabbar I et al. Proteolysisinduced N-Terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-Terminal domain and recruitment of Src and PKCdelta. J Biol Chem 2010; 285: 26162-26173.
25. Brown TA, Yang TM, Zaitsevskaia T, Xia Y, Dunn CA, Sigle RO et al. Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia. J Biol Chem 2004; 279: 14772-14783.
26. Casar B, He Y, Iconomou M, Hooper JD, Quigley JP, Deryugina EI. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells. Oncogene 2012; 31: 3924-3938.
27. Benes CH, Poulogiannis G, Cantley LC, Soltoff SP. The SRC-associated protein CUB domain-containing protein-1 regulates adhesion and motility. Oncogene 2012; 31: 653-663.
28. Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP. The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell 2005; 121: 271-280.
29. Singh R, Lei P, Andreadis ST. PKC-delta binds to E-cadherin and mediates EGF-induced cell scattering. Exp Cell Res 2009; 315: 2899-2913.
30. Busso N, Belin D, Failly-Crepin C, Vassalli JD. Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231. Cancer Res 1987; 47: 364-370.
31. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91: 764-770.
32. Miyagawa R, Asakura T, Nakamura T, Okada H, Iwaki S, Sobel BE et al. Increased expression of plasminogen activator inhibitor type-1 (PAI-1) in HEPG2 cells induced by insulin mediated by the 3'-untranslated region of the PAI-1 gene and its pharmacologic implications. Coron Artery Dis 2010; 21: 144-150.
33. Ying Y, Liu Y, Byeon SR, Kim H, Luesch H, Hong J. Synthesis and activity of largazole analogues with linker and macrocycle modification. Org Lett 2008; 10: 4021-4024.
34. Liu Y, Salvador LA, Byeon S, Ying Y, Kwan JC, Law BK et al. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. J Pharmacol Exp Ther 2010; 335: 351-361.
35. Cole KE, Dowling DP, Boone MA, Phillips AJ, Christianson DW. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J Am Chem Soc 2011; 133: 12474-12477.
36. Wong AS, Gumbiner BM. Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol 2003; 161: 1191-1203.
37. Boulos F, Fedda F. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol 2011; 35: 154-155.
38. Rakha EA, Patel A, Powe DG, Benhasouna A, Green AR, Lambros MB et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol 2010; 34: 1472-1479.
39. Querzoli P, Coradini D, Pedriali M, Boracchi P, Ambrogi F, Raimondi E et al. An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. Br J Cancer 2010; 103: 1835-1839.
40. Zhang X, Hashemi SS, Yousefi M, Gao C, Sheng J, Ni J et al. Atypical E-cadherin expression in cell clusters overlying focally disrupted mammary myoepithelial cell layers: implications for tumor cell motility and invasion. Pathol Res Pract 2009; 205: 375-385.
41. Rubenstein NM, Guan Y, Woo PL, Firestone GL. Glucocorticoid down-regulation of RhoA is required for the steroid-induced organization of the junctional complex and tight junction formation in rat mammary epithelial tumor cells. J Biol Chem 2003; 278: 10353-10360.
42. Buse P, Woo PL, Alexander DB, Reza A, Firestone GL. Glucocorticoid- induced functional polarity of growth factor responsiveness regulates tight junction dynamics in transformed mammary epithelial tumor cells. J Biol Chem 1995; 270: 28223-28227.
43. Zettl KS, Sjaastad MD, Riskin PM, Parry G, Machen TE, Firestone GL. Glucocorticoidinduced formation of tight junctions in mouse mammary epithelial cells in vitro. Proc Natl Acad Sci USA 1992; 89: 9069-9073.
44. Wortmann A, He Y, Christensen ME, Linn M, Lumley JW, Pollock PM et al. Cellular settings mediating src substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) Tyrosine 734. J Biol Chem 2011; 286: 42303-42315.
45. Smith AL, Dohn MR, Brown MV, Reynolds AB. Association of Rho-associated protein kinase 1 with E-cadherin complexes is mediated by p120-catenin. Mol Biol Cell 2012; 23: 99-110.
46. Lewis JE, Wahl III JK, Sass KM, Jensen PJ, Johnson KR, Wheelock MJ. Cross-Talk between adherens junctions and desmosomes depends on plakoglobin. J Cell Biol 1997; 136: 919-934.
47. Levy L, Wei Y, Labalette C, Wu Y, Renard CA, Buendia MA et al. Acetylation of betacatenin by p300 regulates beta-catenin-Tcf4 interaction. Mol Cell Biol 2004; 24: 3404-3414.
48. Wolf D, Rodova M, Miska EA, Calvet JP, Kouzarides T. Acetylation of beta-catenin by CREB-binding protein (CBP). J Biol Chem 2002; 277: 25562-25567.
49. Gomez-Hernandez J, Orozco-Alatorre AL, Dominguez-Contreras M, Oceguera- Villanueva A, Gomez-Romo S, Alvarez Villasenor AS et al. Preoperative dexamethasone reduces postoperative pain, nausea and vomiting following mastectomy for breast cancer. BMC Cancer 2010; 10: 692.
50. Pan D, Kocherginsky M, Conzen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res 2011; 71: 6360-6370.
51. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28: 1684-1691.
52. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 2009; 45(Suppl 1): 27-40.
53. Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME et al. Rapamycin potentiates transforming growth factor beta-induced growth arrest innontransformed, oncogene-Transformed, and human cancer cells. Mol Cell Biol 2002; 22: 8184-8198.
54. Law M, Forrester E, Chytil A, Corsino P, Green G, Davis B et al. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res 2006; 66: 1070-1080.
55. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.
56. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
57. Ireton RC, Davis MA, van Hengel J, Mariner DJ, Barnes K, Thoreson MA et al. A novel role for p120 catenin in E-cadherin function. J Cell Biol 2002; 159: 465-476.
58. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-Titer recombinant retrovirus. Hum Gene Ther 1996; 7: 1405-1413.
59. Swift S, Lorens J, Achacoso P, Nolan GP. Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol 2001; Chapter 10: Unit 10 17C.
60. Chytil A, Waltner-Law M, West R, Friedman D, Aakre M, Barker D et al. Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes. J Biol Chem 2004; 279: 47688-47698.
61. Sheffield J, Taylor N, Fauquet C, Chen S. The cassava (Manihot esculenta Crantz) root proteome: protein identification and differential expression. Proteomics 2006; 6: 1588-1598.
62. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002; 74: 5383-5392.
63. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003; 75: 4646-4658.
64. Zhu M, Simons B, Zhu N, Oppenheimer DG, Chen S. Analysis of abscisic acid responsive proteins in Brassica napus guard cells by multiplexed isobaric tagging. J Proteomics 2010; 73: 790-805.